SCHEMBL517002

SCHEMBL517002

COC(=O)c1ccc(OBOc2ccc(C(=O)OC)c(OC)c2)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.54
TP53 P04637 2/20 0.49
NPC1 O15118 2/20 0.49
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 4/20 0.47
HPGD P15428 4/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 3/20 0.47
GAA P10253 2/20 0.47
GLA P06280 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PKM P14618 1/20 0.46
HTT P42858 1/20 0.46
LMNA P02545 1/20 0.45
RAB9A P51151 1/20 0.45
POLB P06746 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
NR4A2 P43354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18310151 0.89 KMT2A (0.52) KMT2ATP53NPC1MEN1ALDH1A1
Methyl 2,4-Dimethoxybenzoate SCHEMBL645462 0.86 KMT2A (0.64) KMT2ATP53NPC1MEN1ALDH1A1
SCHEMBL5704196 0.82 TP53 (0.46) KMT2ATP53MEN1ALDH1A1GAA
SCHEMBL516908 0.81 KDM4E (0.45) ALDH1A1HPGDMAPTSMN1; SMN2KDM4E
SCHEMBL1500933 0.80 KDM4E (0.58) KMT2ATP53NPC1MEN1ALDH1A1
SCHEMBL5431477 0.80 ALDH1A1 (0.53) KMT2ATP53NPC1MEN1ALDH1A1
SCHEMBL364906 0.80 CPS1 (0.45) KMT2AALDH1A1HPGDMAPTKDM4E
SCHEMBL516293 0.80 ABL1 (0.46) KMT2ANPC1MEN1ALDH1A1HPGD
SCHEMBL5704028 0.79 HIF1A (0.47) KMT2AMEN1ALDH1A1POLB
SCHEMBL5438827 0.79 KMT2A (0.49) KMT2ATP53NPC1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112812114-B Isoxazole derivative, pharmaceutical composition containing same, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2024-05-28 CN disclosed
CN-108329311-B Tricyclic compound as selective estrogen receptor down-regulator and application thereof 南京圣和药业股份有限公司 2022-02-22 CN disclosed
CN-108299420-B Pentacyclic compounds as selective estrogen receptor down-regulators and uses thereof 南京圣和药业股份有限公司 2021-10-15 CN disclosed
CN-112812114-A Isoxazole derivative, pharmaceutical composition containing isoxazole derivative, and preparation method and application of isoxazole derivative 四川科伦博泰生物医药股份有限公司 2021-05-18 CN disclosed
EP-2528903-B1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INT (DE) 2016-07-20 EP disclosed
US-20160199383-A1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INT (DE) 2016-07-14 US disclosed
US-9321771-B2 5-alkynyl-pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-04-26 US disclosed
EP-2421846-B1 5-ALKYNYL-PYRIDINES BOEHRINGER INGELHEIM INT (DE) 2016-01-06 EP disclosed
US-9090564-B2 5-alkynyl-pyridines BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2015-07-28 US disclosed
US-20140073621-A1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-03-13 US disclosed
US-8633183-B2 5-alkynyl-pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 US disclosed
US-20130196975-A1 5-ALKYNYL-PYRIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-08-01 US disclosed
WO-2012170371-A1 COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS N30 PHARMACEUTICALS, LLC (US) 2012-12-13 WO disclosed
EP-2528903-A1 5-ALKYNYL-PYRIMIDINES Boehringer Ingelheim International GmbH (DE) 2012-12-05 EP disclosed
EP-2421846-A1 5-ALKYNYL-PYRIDINES Boehringer Ingelheim International GmbH (DE) 2012-02-29 EP disclosed
US-20120028952-A1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-02 US disclosed
WO-2011092198-A1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-04 WO disclosed
US-20110098275-A1 5-ALKYNYL-PYRIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-28 US disclosed
WO-2010122069-A1 5-ALKYNYL-PYRIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 WO disclosed
EP-2020404-A1 Cyanomethyl substituted N-Acyl Tryptamines Bayer Schering Pharma Aktiengesellschaft (DE) 2009-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160199383-A1 5-ALKYNYL-PYRIMIDINES MKI67, CCNA1, CCNT1 KMT2A 3081/4885TP53 74/4885NPC1 664/4885
US-20130196975-A1 5-ALKYNYL-PYRIDINES MKI67, KIT, CCNA1 KMT2A 1745/4885TP53 85/4885NPC1 1756/4885
US-20140073621-A1 5-ALKYNYL-PYRIMIDINES MKI67, CCNA1, CCNT1 KMT2A 3081/4885TP53 74/4885NPC1 664/4885
US-20120028952-A1 5-ALKYNYL-PYRIMIDINES MKI67, CCNA1, CCNT1 KMT2A 3081/4885TP53 74/4885NPC1 664/4885
US-20110098275-A1 5-ALKYNYL-PYRIDINES MKI67, KIT, CCNA1 KMT2A 1745/4885TP53 85/4885NPC1 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.